[18F]FDG PET/CT for therapeutic assessment of Abatacept in early-onset polymyalgia rheumatica

Conclusion[18F] FDG PET/CT uptake did not decrease significantly after ABA compared to placebo in anatomical areas usually affected in PMR patients. These results are correlated with the clinical-biological therapeutic assessment.Clinical trial registrationThe study was approved by the appropriate ethics committee (CPP Sud-Est II Ref CPP: 2018 –33), and all patients gave their written informed consent before study enrollment.The protocol was registered on Clinicaltrials.gov (NCT03632187).
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research